CTCs in early breast cancer: A path worth taking

Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.

Saved in:
Bibliographic Details
Published in:Cancer letters 2016-07, Vol.376 (2), p.205-210
Main Authors: Maltoni, Roberta, Gallerani, Giulia, Fici, Pietro, Rocca, Andrea, Fabbri, Francesco
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Biomarkers, Tumor - blood
Biopsy
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer therapies
Circulating tumor cells
Clinical evidence
Conflicts of interest
Drug resistance
Early breast cancer
Early Detection of Cancer - methods
Female
Hematology, Oncology and Palliative Medicine
Humans
Liquid biopsy
Lymphatic system
Medical prognosis
Metastasis
Mortality
Neoplasm Metastasis
Neoplasm, Residual
Neoplastic Cells, Circulating - drug effects
Neoplastic Cells, Circulating - metabolism
Neoplastic Cells, Circulating - pathology
Predictive Value of Tests
Surgery
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • CTC value in early breast cancer (EBC) is still not fully accepted. • CTCs are proving a great potential in EBC. • CTCs will contribute to a better understanding and clinical management of EBC.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2016.03.051